Practice
Open Access
Drug eruption associated with empagliflozin
Kevin Yau, Stephanie Poon and Bourne L. Auguste
CMAJ December 12, 2022 194 (48) E1651-E1652; DOI: https://doi.org/10.1503/cmaj.220934
Kevin Yau
Divisions of Nephrology (Yau, Auguste) and Cardiology (Poon), Department of Medicine, Sunnybrook Health Sciences Centre, Temerty Faculty of Medicine, University of Toronto, Toronto, Ont.
MDStephanie Poon
Divisions of Nephrology (Yau, Auguste) and Cardiology (Poon), Department of Medicine, Sunnybrook Health Sciences Centre, Temerty Faculty of Medicine, University of Toronto, Toronto, Ont.
MD MScBourne L. Auguste
Divisions of Nephrology (Yau, Auguste) and Cardiology (Poon), Department of Medicine, Sunnybrook Health Sciences Centre, Temerty Faculty of Medicine, University of Toronto, Toronto, Ont.
MD MSc
Data supplements
Online appendix
Related Articles
- Yau, K., Poon, S., & Auguste, B. L. (2023). Éruption cutanée d’origine médicamenteuse associée à l’empagliflozine. CMAJ, 195(11), E430-E431. Accessed September 30, 2023. https://doi.org/10.1503/cmaj.220934-f.
In this issue
Article tools
Respond to this article
Drug eruption associated with empagliflozin
Kevin Yau, Stephanie Poon, Bourne L. Auguste
CMAJ Dec 2022, 194 (48) E1651-E1652; DOI: 10.1503/cmaj.220934
Related Articles
Cited By...
- No citing articles found.